|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1981-10-29
|
|
pubmed:abstractText |
The cooperative study COALL-80 is derived from the BFM-78-study. The aim of the study is a reduction of the initial therapy-morbidity and -mortality without loss of efficacy by omitting asparaginase from the four drug-induction regimen and interposing it between induction- and CNS-therapy phase. The expected two years disease free survival rate of a pilot study will be 82%. This finding is hitherto comparable with the BFM-study results.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0300-8630
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
193
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
155-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:6943388-6-Mercaptopurine,
pubmed-meshheading:6943388-Adolescent,
pubmed-meshheading:6943388-Child,
pubmed-meshheading:6943388-Child, Preschool,
pubmed-meshheading:6943388-Cyclophosphamide,
pubmed-meshheading:6943388-Cytarabine,
pubmed-meshheading:6943388-Female,
pubmed-meshheading:6943388-Humans,
pubmed-meshheading:6943388-Infant,
pubmed-meshheading:6943388-Leukemia, Lymphoid,
pubmed-meshheading:6943388-Male,
pubmed-meshheading:6943388-Methotrexate,
pubmed-meshheading:6943388-Prednisone,
pubmed-meshheading:6943388-Prognosis,
pubmed-meshheading:6943388-Vincristine
|
|
pubmed:year |
1981
|
|
pubmed:articleTitle |
[Presentation of the cooperative study COALL-80 on treatment of childhood ALL (author's transl)].
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
